APPLICATIONS OF LONG-READ SEQUENCING IN CLINICAL GENOMICS
Dr Ira Deveson,
Laboratory Head
Genomic Technologies Research Lab,
Garvan Institute of Medical Research,
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | October 2026
Dr Ira Deveson is a mid-career researcher and Snow Fellow. He has expertise in clinical genomics, biotechnology development and bioinformatics, with his lab focusing on applications of long-read sequencing in clinical genomics. His work spans from computational methods development and software/hardware engineering, to large-scale genomic analysis of diverse cohorts in health and disease.
Dr Ira Deveson graduated with a Bachelor of Philosophy from the Australian National University in 2012. He completed a PhD at the Garvan Institute of Medical Research from 2014-2017, supervised by Prof John Mattick and Dr Tim Mercer. Dr Deveson’s PhD focused on genome/transcriptome research and bioinformatics, and earned him recognition with the JD Catcheside prize from the Genetics Society of Australasia.
Dr Deveson was appointed as Head of Garvan’s Genomic Technologies Lab in 2020 and has since been awarded multiple significant NHMRC and MRFF grants to support his work on long-read sequencing technology development. He currently holds an NHMRC Investigator Grant (L1) and a prestigious Snow Medical Fellowship. His research has been published in leading science journals including Nature, Nature Biotechnology and Nature Methods. In addition to his research role, Dr Deveson leads the Long-read Sequencing Hub within Garvan’s Genomics Platform.
Source: Supplied
https://orcid.org/0000-0003-3861-0472
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Cellular mechanisms of traumatic brain injury & concussion
Professor Melinda Fitzgerald is Deputy Vice Chancellor, Research at Curtin University, John Curtin Distinguished Professor and CEO of Connectivity Traumatic Brain Injury Australia.
She has published over 135 papers; recent highlights include Lancet Neurology, J Neuroscience, Nature Nano, ACS Nano, Biomaterials. Currently held grants/Projects total $10.1 million; CIA for $5.2 million of these; $18.5 million total research and equipment funding, $9.9 million as CIA; continuous category 1 grant funding as CIA since 2009.
-
Mental health research on first responders in regional, rural and remote Australia
Dr Rikki Jones has been awarded to date a total of over $430,000 in research funding. She is currently leading four large national research teams focusing on rural health and sustainable rural health workforce (include mental health of first responders, sexual violence in rural Australia, virtual simulated nursing placements, and nursing students experience with online learning, connection and transitioning to practice).
